Alzheon Highlighted as One of the “Top 20 Life Science Startups to Watch in the U.S.”

Alzheon is focused on developing treatments for patients with Alzheimer’s disease and other neurological and psychiatric disorders. The company’s lead clinical product candidate, ALZ-801, is an oral inhibitor of amyloid aggregation and neurotoxicity—hallmarks of Alzheimer’s disease. ALZ-801 is an optimized, novel prodrug that builds on the safety and efficacy profile of the active compound.
Alzheon completed a $10 million Series A round of financing in April 2015 and has started a Phase I clinical trial for ALZ-801.

As quoted from biospace.com.  Read the full article here
2016-12-06T09:22:02+00:00 January 26th, 2016|Tags: |